Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 257

The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.

Resistance to Somatostatin Analogs in Acromegaly

Colao, Annamaria, Auriemma, Renata S., Lombardi, Gaetano, Pivonello, Rosario·2011·Endocrine Reviews
DOI 10.1210/er.2010-0002
Open this paper in CoChat — free account

Abstract

Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. First-line treatment with these drugs is generally used in the patients with macroadenomas or in those with clinical conditions so severe as to prevent unsafe reactions during anesthesia. Generally, the response to SA takes into account both control of GH and IGF-I excess, with consequent improvement of clinical symptoms directly related to GH and IGF-I excess, and tumor shrinkage. This latter effect is more prominent in the patients treated first-line and bearing large macroadenomas, but it is also observed in patients with microadenomas, even with little clinical implication. Predictors of response are patients' gender, age, initial GH and IGF-I levels, and tumor mass, as well as adequate expression of somatostatin receptor types 2 and 5, those with the highest affinity for octreotide and lanreotide. Only sporadic cases of somatostatin receptor gene mutation or impaired signaling pathways have been described in GH-secreting tumors so far. The response to SA also depends on treatment duration and dosage of the drug used, so that a definition of resistance based on short-term treatments using low doses of long-acting SA is limited. Current data suggest that response to these drugs is better analyzed taking together biochemical and tumoral effects because only the absence of both responses might be considered as a poor response or resistance. This latter evidence seems to occur in 25% of treated patients after 12 months of currently available long-acting SA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2010-0002

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 130 references

Cited by

See all 257

Metadata

Authors
Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R.
Venue
Endocrine Reviews
Publisher
The Endocrine Society
Published
2010-12-01
Volume
32
Issue
2
Pages
247-271
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
DOI
10.1210/er.2010-0002
OpenAlex
W2158629056
Cited by
257
References
130
FWCI
9.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance to Somatostatin Analogs in Acromegaly. https://app.cochat.ai/papers/10.1210/er.2010-0002
The paper
Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R. (2011). Resistance to Somatostatin Analogs in Acromegaly. Endocrine Reviews. https://doi.org/10.1210/er.2010-0002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.